Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yestar Healthcare Holdings Co Ltd ( (HK:2393) ) has issued an update.
Yestar Healthcare has warned that it expects to swing to a consolidated net loss of at least RMB65 million for the year ended 31 December 2025, compared with a net profit of about RMB903.5 million a year earlier. The company attributes the reversal mainly to the absence of a one-off gain of roughly RMB1,083.4 million booked in 2024 from discounted redemption of its 2026 senior notes and to impairment losses on non-financial assets recognised in 2025.
The FY2025 figures are based on preliminary unaudited management accounts and may be adjusted once the audited results are finalized, with the full annual results slated for release on 27 March 2026. The profit warning signals a sharp deterioration in headline earnings quality after last year’s exceptional gain, and the company has urged shareholders and potential investors to exercise caution when dealing in its shares pending publication of the audited results.
The most recent analyst rating on (HK:2393) stock is a Sell with a HK$0.11 price target. To see the full list of analyst forecasts on Yestar Healthcare Holdings Co Ltd stock, see the HK:2393 Stock Forecast page.
More about Yestar Healthcare Holdings Co Ltd
Yestar Healthcare Holdings Company Limited is a Hong Kong-listed healthcare group incorporated in the Cayman Islands and traded under stock code 2393. The company operates through various subsidiaries, focusing on healthcare-related products and services in the Greater China market, and is overseen by a board comprising executive, non-executive, and independent non-executive directors.
Average Trading Volume: 873,459
Technical Sentiment Signal: Sell
Current Market Cap: HK$244.6M
For a thorough assessment of 2393 stock, go to TipRanks’ Stock Analysis page.